Get all premium features to the best stock analysis tool

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Gaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development. The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates.

E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as the exclusive placement agent in connection with a $3.5 million public offering by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (“Shuttle Pharmaceuticals” or the “Company”), the owner of Molecule.ai, an artificial intelligence (“AI”) driven platform for molecular discovery and early-stage drug development.

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Gaithersburg, Maryland--(Newsfile Corp. - March 6, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, today announced that it has entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common stock, in a public offering, for aggregate gross proceeds of approximately $3,500,000, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions.